Claritev Corporation (CTEV) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 4.99 means the share price is 4.99 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $626M is the value of all shares combined. Beta 0.54: the stock has moved about 46% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerClaritev Corporation (CTEV) trades at $36.74 with MoonshotScore 21/100 (Grade F). Claritev Corporation provides data analytics and technology-enabled cost management solutions to the healthcare industry. Market cap: $626M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: May 10, 2026CTEV stock analysis for 2026: Analysts have set a consensus price target of $52.00 for Claritev Corporation, suggesting 41.5% upside from the current price of $36.74. The AI MoonshotScore is 21/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
These figures come from statements filed 12 months ago — the most recent this company has published.
CTEV: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Strongest side: Momentum (7/10, Moderate). Weakest side: Financial Safety (3/10, Weak).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Claritev Corporation (CTEV) Healthcare & Pipeline Overview
Claritev Corporation delivers data analytics and cost management solutions to the healthcare industry, leveraging technology to reduce medical costs and improve payment accuracy. With a focus on data-driven insights and network-based services, Claritev serves national and regional insurance companies, aiming to optimize benefit plan designs and clinical outcomes.
What Is the Investment Thesis for CTEV?
Claritev Corporation operates in the growing healthcare cost containment market. With a market capitalization of $626M, the company's analytics-based services offer potential for growth as healthcare providers and insurers seek to reduce costs and improve efficiency. The company's gross margin of 61.1% indicates a strong ability to generate profit from its services. Key value drivers include the increasing demand for data-driven cost management solutions in healthcare and the company's ability to expand its customer base. A potential risk is the company's negative profit margin of -29.3%, which needs to be addressed for long-term sustainability. The beta of 0.54 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
CTEV Key Highlights
Market Cap of $626M reflects the company's current valuation in the healthcare information services sector.
- Gross Margin of 61.1% indicates strong profitability from core services, suggesting efficient cost management.
- Profit Margin of -29.3% highlights a need for improved cost control and revenue generation strategies.
- Beta of 0.54 suggests lower volatility compared to the market, potentially appealing to risk-averse investors.
- Services cater to national and regional insurance companies, providing a stable and recurring revenue stream.
Who Are CTEV's Competitors?
CTEV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| DNTH Dianthus Therapeutics, Inc. | $108.71 | +5.26% | $6.08B | — |
| PHR Phreesia, Inc. | $10.17 | -1.64% | $629M | 685-pillar |
| SOPH SOPHiA GENETICS SA | $7.61 | -0.91% | $638M | — |
| ACCD Accolade, Inc. | $7.02 | 0.00% | $576M | — |
| MDRX Veradigm Inc. | $4.55 | -2.15% | $773M | 509-signal |
| NRC National Research Corporation | $21.07 | -0.89% | $475M | 725-pillar |
| EVH Evolent Health, Inc | $4.17 | +0.48% | $469M | — |
| HSTM HealthStream, Inc. | $28.91 | +0.10% | $845M | 885-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CTEV's Key Strengths?
Strong expertise in data analytics and cost management.
- Established relationships with major insurance companies.
- Comprehensive suite of services covering payment and revenue integrity.
- Technology-enabled solutions for efficient claims processing.
What Are CTEV's Weaknesses?
Negative profit margin (-29.3%) indicates financial challenges.
- Reliance on the healthcare industry makes it susceptible to regulatory changes.
- Limited geographic diversification.
- Dependence on data accuracy and security.
What Could Drive CTEV Stock Higher?
Expansion of data and decision science services to drive revenue growth.
- Strategic partnerships with healthcare providers to enhance service offerings.
- Potential acquisitions of complementary businesses to expand market share.
- Development of new technology solutions using AI and machine learning.
- Continued focus on improving cost management and payment integrity for clients.
What Are the Key Risks for CTEV?
Financial-distress signal — its Altman Z-Score of -0.42 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Negative profit margin (-29.3%) poses a risk to financial sustainability.
- Changes in healthcare regulations and reimbursement policies could impact revenue.
- Data security breaches and privacy concerns could damage reputation and incur costs.
- Increasing competition from other healthcare information service providers.
- Economic downturn affecting healthcare spending could reduce demand for services.
What Are the Growth Opportunities for CTEV?
- Expansion of Data and Decision Science Services: Claritev can expand its data and decision science services to offer more sophisticated analytics solutions. The market for healthcare analytics is projected to reach $45 billion by 2028, driven by the need for better insights into patient outcomes and cost management. By leveraging its existing data assets and expertise, Claritev can develop predictive and prescriptive analytics tools that drive optimized benefit plan design and improve clinical outcomes. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with healthcare providers can enhance Claritev's service offerings and expand its market reach. Collaborating with providers allows Claritev to integrate its solutions directly into clinical workflows, improving the accuracy and efficiency of cost management processes. These partnerships can also provide access to valuable data and insights, further enhancing the company's analytics capabilities. Timeline: Ongoing.
- Geographic Expansion: Claritev can expand its services to new geographic markets, both domestically and internationally. The demand for healthcare cost management solutions is global, and Claritev's expertise can be applied to address similar challenges in other countries. By targeting regions with high healthcare costs and complex regulatory environments, Claritev can tap into new revenue streams and diversify its customer base. Timeline: Upcoming.
- Development of New Technology Solutions: Investing in the development of new technology solutions can differentiate Claritev from its competitors and enhance its value proposition. This includes exploring AI and machine learning technologies to automate and improve the accuracy of claims processing and cost management. By staying at the forefront of technological innovation, Claritev can attract new customers and retain existing ones. Timeline: Ongoing.
- Acquisition of Complementary Businesses: Claritev can pursue strategic acquisitions of complementary businesses to expand its service offerings and market share. Acquiring companies with expertise in areas such as healthcare IT, data analytics, or payment processing can enhance Claritev's capabilities and create synergies that drive growth. This strategy can also provide access to new customers and markets. Timeline: Upcoming.
What Are CTEV's Competitive Advantages?
- Proprietary data analytics algorithms for cost management.
- Established network of healthcare providers offering contracted discounts.
- Expertise in payment and revenue integrity services.
- Long-standing relationships with national and regional insurance companies.
What Does CTEV Do?
Founded in 1980 and formerly known as MultiPlan Corporation until its rebranding in February 2025, Claritev Corporation provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company's core offerings revolve around reducing medical costs through advanced data analytics, identifying claims over-charges, and negotiating reimbursements. Claritev also provides network-based services, offering contracted discounts with healthcare providers and outsourced network development and management. Its payment and revenue integrity services focus on identifying and removing improper charges, while also working to restore underpaid premium dollars. Additionally, Claritev offers data and decision science services, using modern data science methods to produce descriptive, predictive, and prescriptive analytics. These analytics drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care. The company serves a diverse clientele, including national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other entities involved in claim adjudication. Headquartered in New York, Claritev Corporation continues to evolve its solutions to meet the changing needs of the healthcare industry.
What Products and Services Does CTEV Offer?
- Provides data analytics solutions for healthcare cost management.
- Offers technology-enabled payment and revenue integrity services.
- Reduces medical costs through data-driven algorithms and insights.
- Detects claims over-charges and negotiates reimbursement.
- Provides contracted discounts with healthcare providers.
- Offers outsourced network development and management services.
- Identifies and removes improper and unnecessary charges paid during the claim.
- Restores and preserves underpaid premium dollars.
How Does CTEV Make Money?
- Generates revenue through analytics-based services that reduce medical costs.
- Provides network-based services offering contracted discounts with healthcare providers.
- Offers payment and revenue integrity services to identify and remove improper charges.
- Provides data and decision science services for optimized benefit plan design.
What Industry Does CTEV Operate In?
Claritev Corporation operates within the healthcare information services industry, which is experiencing growth due to increasing pressure to manage healthcare costs and improve outcomes. The industry is characterized by the adoption of data analytics and technology-enabled solutions to streamline processes and reduce inefficiencies. Claritev competes with other companies offering similar cost management and payment integrity services. The company's focus on data-driven insights and comprehensive solutions positions it to capitalize on the growing demand for healthcare cost containment strategies.
Who Are CTEV's Key Customers?
- National and regional insurance companies
- Blue Cross and Blue Shield plans
- Provider-sponsored and independent health plans
- TPAs (Third Party Administrators)
- Self-insured health plans
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 91% of our measures
- ● Price is current
- ● Latest filing 35 days ago
- ● Covered by analysts
Why 21?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.78 Return on equity (Business Quality)
- +0.32 6-month price trend (Momentum)
- +0.30 Operating income growth (Growth)
What is holding it back
- -0.60 Net debt vs earnings (Financial Strength)
- -0.34 Net margin (Business Quality)
- -0.22 Earnings yield (Valuation)
Risk penalties applied
- -1.37 Bankruptcy-risk score in the distress zone
- -1.43 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 20 |
| 2026-08-26 | 20 |
| 2026-08-29 | 20 |
| 2026-09-01 | 22 |
| 2026-09-04 | 21 |
| 2026-09-07 | 21 |
| 2026-09-10 | 21 |
What changed?
The grade moved from 20 to 21 (+1).
What moved it up or down:
- +12 Valuation
- +4 Momentum
- +2 Business Quality
Held back by:
- -30 Financial Safety
Over the same 18 days the stock moved -2.6%.
Company Profile
Claritev Corporation operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in McLean, US. The company is led by CEO Travis S. Dalton. CTEV has traded publicly since 2020.
Claritev Corporation Financial Trajectory
Claritev Corporation (CTEV) reported $257.5M in revenue for Q2 FY2026, reflecting 5.2% growth compared to the prior quarter. The company recorded a net loss of $59.2M, with diluted EPS of $-3.49. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, CTEV averaged $-4.26 in diluted EPS.
How Claritev Corporation Is Valued
Claritev Corporation carries a market capitalization of $626M, placing it in the small-cap category. Analyst price targets span from $40.00 to $73.00, with a consensus of $52.00. At the current price of $36.74, that implies approximately 42% upside potential. Relative to its peer group, CTEV's quantitative score of 21/100 is below the peer average of 70/100.
Key Financial Metrics
Return on assets is 1.1%, showing how much profit it generates from its asset base. CTEV trades at a trailing price-to-earnings ratio of 4.99, below the Healthcare sector average of ~21.50x. A current ratio of 1.28 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Claritev Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.42 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Claritev Corporation has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 203.0% below estimates on average.
Insider Activity
Over the past six months, Claritev Corporation insiders filed 21 SEC Form 4 transactions — 4 sales and 17 purchases. On net that is roughly 79K shares acquired (about $278K) — insiders putting money in tends to read as conviction.
CTEV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong expertise in data analytics and cost management.
- Established relationships with major insurance companies.
- Comprehensive suite of services covering payment and revenue integrity.
- Technology-enabled solutions for efficient claims processing.
Bear Case
- Negative profit margin (-29.3%) indicates financial challenges.
- Reliance on the healthcare industry makes it susceptible to regulatory changes.
- Limited geographic diversification.
- Dependence on data accuracy and security.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $257M | -$59M | -$3.49 |
| Q1 FY2026 | $245M | -$74M | -$4.41 |
| Q4 FY2025 | $247M | -$81M | -$4.90 |
| Q3 FY2025 | $246M | -$70M | -$4.23 |
Q2 FY2026 · filed 7 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
CTEV Latest News
-
Claritev’s (CTEV) Profit Picture Brightens, But Its Cash Cushion Shrinks
Yahoo! Finance: CTEV News · Sep 8, 2026
-
Claritev Corporation Announces Participation in Upcoming Events
businesswire.com · Aug 27, 2026
-
Barclays Maintains Overweight on Claritev, Raises Price Target to $40
benzinga · Aug 21, 2026
-
Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans
benzinga · Aug 17, 2026
CTEV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CTEV.
Price Targets
Median: $43.00 (+41.5% from current price)
Source: FMP analyst consensus · as of Aug 25, 2026 · an estimate, not advice
CTEV MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. CTEV scores 21/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
Claritev’s (CTEV) Profit Picture Brightens, But Its Cash Cushion Shrinks
Claritev Corporation Announces Participation in Upcoming Events
Barclays Maintains Overweight on Claritev, Raises Price Target to $40
Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans
Leadership: Travis S. Dalton
CEO
Travis S. Dalton is the CEO of Claritev Corporation, leading a team of 2700 employees. His background includes extensive experience in the healthcare technology and data analytics sectors. Prior to joining Claritev, Dalton held leadership positions at various healthcare companies, where he focused on developing and implementing innovative solutions to improve healthcare outcomes and reduce costs. He holds an MBA from a top-tier business school and a bachelor's degree in computer science.
Track Record: Since becoming CEO, Travis S. Dalton has focused on expanding Claritev's data and decision science services and strengthening its relationships with key clients. He has overseen the rebranding of the company from MultiPlan Corporation to Claritev Corporation in February 2025, signaling a renewed focus on innovation and growth. Dalton's strategic decisions have aimed to position Claritev as a leader in healthcare cost management and payment integrity.
CTEV Healthcare Stock FAQ
What does the AI Score mean for CTEV?
CTEV holds an AI Score of 21/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Claritev Corporation provides data analytics and technology-enabled cost management solutions to the healthcare industry.
Is CTEV a good stock?
Stock Expert AI does not rate CTEV buy, sell or hold. Claritev Corporation carries a MoonshotScore of 21/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CTEV stock?
Analyst coverage of Claritev Corporation (CTEV) is limited based on available data. Key valuation metrics to consider include the company's market capitalization of $626M and its gross margin of 61.1%. However, the negative profit margin of -29.3% is a concern.
What are the key factors to evaluate for CTEV?
Claritev Corporation (CTEV) holds a MoonshotScore of 21/100 (low). P/E: 4.99x vs the S&P 500's ~20-25x. Analysts target $52.00 (+42%). Not financial advice.
How frequently does CTEV data refresh on this page?
CTEV's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CTEV's recent stock price performance?
Claritev Corporation (CTEV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong expertise in data analytics and cost management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CTEV overvalued or undervalued right now?
Claritev Corporation (CTEV) trades at 4.99x earnings. Analysts target $52.00 (+42%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CTEV?
Yes, most major brokerages offer fractional shares of Claritev Corporation (CTEV) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CTEV's earnings and financial reports?
Claritev Corporation (CTEV) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CTEV earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited to market cap, profit margin, and gross margin.
- AI Insight is based on limited information.